Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPIP formulation bioavailability study in healthy volunteers
NCT07102316Phase 1Completed
- Sponsor
- Insmed Incorporated
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Inhalation Devices, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of treprostinil palmitil (3 arms), sponsored by Insmed Incorporated. Primary endpoints: Maximum Observed Plasma Concentration of Treprostinil, Area Under Plasma Concentration-Time Curve From 0 to Last Time Point With Quantifiable Concentration of Treprostinil and 1 more. Started Aug 2025; status: completed.
02
Drugs
treprostinil palmitil
Beyond the preview
Go deeper on NCT07102316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07102316.